Who
Jane Chung
Chief Executive Officer
Company insider
Files Form 4 as: Chief Executive Officer, Sutro Biopharma; Director, Viracta Therapeutics.
In numbers
- Trades disclosed
- 77
- Buys
- 1
- Sells
- 0
- Bought
- $10K
- Sold
- $0
- Companies
- 2
- Companies where not an officer
- 1
- First trade
- 9 Aug 2021
- Last trade
- 4 Mar 2026
- Last filed
- 6 Mar 2026
Companies traded
Activity over time
1 Oct 2025 – 1 Oct 2026
Buys above the line, sells below, each month.
Every trade
| Traded | Company | What | Amount | |
|---|---|---|---|---|
| 4 Mar 2026filed 6 Mar 2026 | STRO Sutro BiopharmaBiotechnology | SEC FORM 4 Code M | —788 at $0.00 | filing |
| 4 Mar 2026filed 6 Mar 2026 | STRO Sutro BiopharmaBiotechnology | SEC FORM 4 Code F | $6,009282 at $21.31 | filing |
| 4 Mar 2026filed 6 Mar 2026 | STRO Sutro Biopharmaoption or derivative · Biotechnology | SEC FORM 4 Code M | —788 at $0.00 | filing |
| 4 Mar 2026filed 6 Mar 2026 | STRO Sutro Biopharmaoption or derivative · Biotechnology | SEC FORM 4 Code M | —788 at $0.00 | filing |
| 4 Mar 2026filed 6 Mar 2026 | STRO Sutro BiopharmaBiotechnology | SEC FORM 4 Code M | —788 at $0.00 | filing |
| 4 Mar 2026filed 6 Mar 2026 | STRO Sutro BiopharmaBiotechnology | SEC FORM 4 Code F | $6,009282 at $21.31 | filing |
| 2 Mar 2026filed 3 Mar 2026 | STRO Sutro Biopharmaoption or derivative · Biotechnology | SEC FORM 4 Code A | —175,000 at $0.00 | filing |
| 2 Mar 2026filed 3 Mar 2026 | STRO Sutro Biopharmaoption or derivative · Biotechnology | SEC FORM 4 Code M | —7,750 at $0.00 | filing |
| 2 Mar 2026filed 3 Mar 2026 | STRO Sutro Biopharmaoption or derivative · Biotechnology | SEC FORM 4 Code A | —40,000 at $0.00 | filing |
| 2 Mar 2026filed 3 Mar 2026 | STRO Sutro Biopharmaoption or derivative · Biotechnology | SEC FORM 4 Code A | —175,000 at $0.00 | filing |
| 2 Mar 2026filed 3 Mar 2026 | STRO Sutro BiopharmaBiotechnology | SEC FORM 4 Code M | —7,750 at $0.00 | filing |
| 2 Mar 2026filed 3 Mar 2026 | STRO Sutro BiopharmaBiotechnology | SEC FORM 4 Code F | $57K2,779 at $20.55 | filing |
| 2 Mar 2026filed 3 Mar 2026 | STRO Sutro Biopharmaoption or derivative · Biotechnology | SEC FORM 4 Code M | —7,750 at $0.00 | filing |
| 2 Mar 2026filed 3 Mar 2026 | STRO Sutro BiopharmaBiotechnology | SEC FORM 4 Code M | —7,750 at $0.00 | filing |
| 2 Mar 2026filed 3 Mar 2026 | STRO Sutro BiopharmaBiotechnology | SEC FORM 4 Code F | $57K2,779 at $20.55 | filing |
| 2 Mar 2026filed 3 Mar 2026 | STRO Sutro Biopharmaoption or derivative · Biotechnology | SEC FORM 4 Code A | —40,000 at $0.00 | filing |
| 1 Mar 2026filed 3 Mar 2026 | STRO Sutro BiopharmaBiotechnology | SEC FORM 4 Code M | —688 at $0.00 | filing |
| 1 Mar 2026filed 3 Mar 2026 | STRO Sutro BiopharmaBiotechnology | SEC FORM 4 Code M | —2,500 at $0.00 | filing |
| 1 Mar 2026filed 3 Mar 2026 | STRO Sutro BiopharmaBiotechnology | SEC FORM 4 Code F | $26K1,271 at $20.47 | filing |
| 1 Mar 2026filed 3 Mar 2026 | STRO Sutro Biopharmaoption or derivative · Biotechnology | SEC FORM 4 Code M | —688 at $0.00 | filing |
News
Tenaya Therapeutics (NASDAQ:TNYA) versus Sutro Biopharma (NASDAQ:STRO) Head-To-Head ComparisonSTRO · themarketsdaily.com · 20 Oct 2026
0 headlines in the last 90 days name Jane Chung; 1 article from the last 14 days about the 1 company they traded most, at most three about any one of them.